Imagen de Portada

T‐cell‐based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	S. Moraru, F. Malard, A. Banet, A. Capes, Agnes Bonnin, N. Stocker, S. Sestili, R. Belhocine, Ludovic Suner, S. Ikhlef, Z. Van de Wyngaert, E. Brissot, Mohamad Mohty, Laure Ricard
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	British Journal of Haematology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Severe cytopenia after chimeric antigen receptor‐T cell driven by large granular lymphocytes and responsive to steroids
por: Antoine Capes, et al.
Publicado: (2024)

Induction prior to autologous haematopoietic cell transplantation in multiple myeloma
por: Mohamad Mohty, et al.
Publicado: (2024)

Allogeneic transplantation in T‐cell lymphomas: A long‐awaited consensus for a field in need of direction
por: Mohamad Mohty, et al.
Publicado: (2026)

The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation
por: Wenjing Hao, et al.
Publicado: (2026)

Teclistamab for relapsed refractory multiple myeloma patients on dialysis
por: P. Lebreton, et al.
Publicado: (2024)

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
por: Michael H. Tomasson, et al.
Publicado: (2024)

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study
por: Olivier Decaux, et al.
Publicado: (2024)

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
por: Syed Naqvi, et al.
Publicado: (2024)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
por: Patrick Born, et al.
Publicado: (2025)

Writing the story of immune effector cell‐associated neurotoxicity syndrome
por: Vincent Bonny, et al.
Publicado: (2024)

Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
por: Deniz Gezer, et al.
Publicado: (2024)

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
por: Cyrille Touzeau, et al.
Publicado: (2025)

Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study
por: Cyrille Hulin, et al.
Publicado: (2024)

Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series
por: Gráinne Marron, et al.
Publicado: (2026)

Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
por: Jing An, et al.
Publicado: (2024)

A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
por: Eric Wenlong Li, et al.
Publicado: (2024)

“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
por: Kevin C. Graf, et al.
Publicado: (2024)

Reseña de "Chinese Folksongs and Folksingers: Shan´ge Traditions in Southern Jiangsu" de Antoinet Schimmelpenninck
por: Daniele Sestili
Publicado: (2002)

Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma
por: Carolina Perrone Marques, et al.
Publicado: (2024)

Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
por: Roxanne C. Jewell, et al.
Publicado: (2024)

Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia
por: Sanaa Khan, et al.
Publicado: (2024)

The Law of the Seabed
por: Banet, Catherine
Publicado: (2020)

Exact MAP inference in general higher-order graphical models using linear programming
por: Bechar, Ikhlef
Publicado: (2017)

Évaluation de la coherence du processus de mise en œuvre du projet pilote de smart meters dans le secteur residentiel à Diar El Bahri (Blida) en Algérie
por: Belhocine Ouahiba
Publicado: (2021)

Similarity solution and Runge Kutta method to a thermal boundary layer model at the entrance region of a circular tube: The Lévêque Approximation
por: Ali Belhocine
Publicado: (2018)

Temperature and Thermal Stresses of Vehicles Gray Cast Brake
por: A. Belhocine
Publicado: (2013)

CFD modeling and computation of convective heat coefficient transfer of automotive disc brake rotors
por: Ali Belhocine
Publicado: (2017)

FEA Analysis of coupled thermo-mechanical response of grey cast iron material used in brake discs
por: Ali Belhocine
Publicado: (2019)

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
por: Xiaoyan Han, et al.
Publicado: (2024)

The role of proliferating stem‐like plasma cells in relapsed or refractory multiple myeloma: Insights from single‐cell RNA sequencing and proteomic analysis
por: Jiadai Xu, et al.
Publicado: (2024)

Investigaciones secuenciadas por grado de autonomía para el desarrollo de prácticas científicas en 2º y 3º de ESO
por: Luisa López-Banet
Publicado: (2023)

Presentación: Formación del Profesorado de Ciencias Naturales de Educación Secundaria
por: Enrique Banet Hernández
Publicado: (2003)

Are transplant strategies in relapsed myeloma relevant in the cellular treatment era?
por: Despina Fotiou, et al.
Publicado: (2025)

Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort
por: Thomas G. Martin, et al.
Publicado: (2026)

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
por: Anna Furlan, et al.
Publicado: (2024)

Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial
por: Maria‐Victoria Mateos, et al.
Publicado: (2024)

An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
por: Prashant Kapoor, et al.
Publicado: (2024)

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T‐cell lymphomas
por: Christina Poh, et al.
Publicado: (2026)

Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag
por: Brynn B. Duncan, et al.
Publicado: (2024)

Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”
Publicado: (2026)